




FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

MKRAWZSENEK@FULBRIGHT.COM
DIRECT DIAL: (512) 536-3020

TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

August 13, 2003

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:	
August 13, 2003	
Date	Michael R. Krawzsenek

MS DD

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

RE: *U.S. Patent Application No. 10/611,803 entitled "PHARMACEUTICAL DOSAGE FORM BEARING PREGNANCY-FRIENDLY INDICIA" – Éric Gervais et al.*
Our reference: GOUD:031US
Client reference: AML/11621.35

Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references C1-C9.

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/GOUD:031US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,



Michael R. Krawzsenek
Reg. No. 51,898

MRK/cmb
Encl.: as noted

25323611.1



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Éric Gervais *et al.*

Serial No.: 10/611,803

Filed: July 1, 2003

For: PHARMACEUTICAL DOSAGE FORM
BEARING PREGNANCY-FRIENDLY
INDICIA

Group Art Unit: Unknown

Examiner: Unknown


Atty. Dkt. No.: GOUD:031US

CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

August 13, 2003

Date


Michael R. Krawzsenek

INFORMATION DISCLOSURE STATEMENT

MS DD

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be

an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/GOUD:031US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Michael R. Krawzsenek
Reg. No. 51,898
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: August 13, 2003

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

GOUD:031US

10/611,803

List of Patents and Publications for Applicant's

Applicant

Éric Gervais *et al.*

INFORMATION DISCLOSURE STATEMENT

Filing Date:

July 1, 2003

Group:

Unknown

(Use several sheets if necessary)

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Anke <i>et al.</i> , "Questions about drugs: how do pregnant women solve them?" <i>Pharm. World Sci.</i> , 26(6):254-259, 1994.
	C2	Czeizel and Dudas, "Prevention of the first occurrence of neural tube defects by periconceptional vitamin supplementation," <i>New England J. Med.</i> , 327:1832-1835, 1992.
	C3	Einarson <i>et al.</i> , "Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counselling," <i>J. Psychiatry Neurosci.</i> , 26(1):44-48, 2001.
	C4	Koren and Pastuszak, "Prevention of unnecessary pregnancy terminations by counseling women on drug, chemical and radiation exposure during the first trimester," <i>Teratology</i> , 41(6):657-661, 1990.
	C5	Matsui, "Drug compliance in pediatrics. Clinical and research issues," <i>Ped. Clin. N. Amer.</i> , 44(1):1-14, 1997.
	C6	Mazzotta <i>et al.</i> , "Factors associated with elective termination of pregnancy among Canadian and American women with nausea and vomiting of pregnancy," <i>J. Psychosom Obstet. Gynecol.</i> , 22(1):7-12, 2001.
	C7	Olesen <i>et al.</i> , "Do pregnant women report use of dispensed medications?" <i>Epidemiology</i> , 12(5):497-501, 2001.
	C8	Pastuszak <i>et al.</i> , "The effectiveness of preconceptional counseling on women's compliance with folic acid supplementation, maternal-fetal toxicology, A clinician's guide," 3 rd Edition, pp. 141-149, 2001.


25323587.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)





Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.

GOUD:031US

Serial No.

10/611,803

Applicant

Éric Gervais *et al.*

Filing Date:

July 1, 2003

Group:

Unknown

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

*See Page 1***Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
	C9	Pole <i>et al.</i> , "Drug labeling and risk perceptions of teratogenicity: A survey of pregnant Canadian women and their health professionals," <i>J. Clin. Pharmacol.</i> , 40:573-577, 2000.

25323587.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)